Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease

Expert Opinion on Investigational Drugs

Volumn 19, Issue 9, 2010, Pages 1027-1037

  Abe, Masanori ^a   Okada, Kazuyoshi ^a   Maruyama, Noriaki ^a,b   Matsumoto, Shiro ^a   Maruyama, Takashi ^a   Fujita, Takayuki ^a   Matsumoto, Koichi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; Benidipine; Calcium channel blocker; Chronic kidney disease; Cilnidipine; Hypertension; Proteinuria

Indexed keywords

BENIDIPINE; CILNIDIPINE; CREATININE; OLMESARTAN; PROTEIN; TELMISARTAN;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFECT; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; SKIN MANIFESTATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CREATININE; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; PROTEINURIA; RECEPTORS, ANGIOTENSIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 77955635116     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.505918     Document Type: Article

References (36)

1. Hcmmclgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-429
2. Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R. Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int 2005;99:S52-6
3. Viberti G, Wheeldon MN.; for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-678
4. Lewis JE, Hunsicker GL, Clarke RW, et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
5. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003;139:244-252
6. Weidmann P, Boehlen LM, Courten M. Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant 1993;8:582-584
7. Lavermann GD, Henning RH, De Jong PE, et al. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001;38:1381-1384
8. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertension Res 2009;32:4-107
9. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC Report. JAMA 2003;289:2560-2572
10. Mancia G, Backer GD, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187 (Pubitemid 46924065)
11. Sheinfield GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999;12:80-85
12. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens 2006;24:19-27
13. Ertel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron 2000;25:533-535
14. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 2000;16:521-555
15. Hayashi K, Wakino S, Homma K, et al. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci 2005;99:221-227
16. Ohishi M, Takagi T, Ito N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an amlodipine-to-benidipine changeover (ABC) study. Hypertens Res 2007;30:797-806
17. Zhou X, Ono H, Ono Y, et al. N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apotosis and proliferation in an I-NAME/SHR model. J Hypertens 2002;20:993-1000
18. Konda T, Enomoto A, Matsushita J, et al. The N-and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a highsucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005;101:1-13
19. Rose GW, Kanno Y, Ikebukuro H, et al. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001;24:377-383
20. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal disease. Hypertens Res 2004;27:379-385
21. Wright JT Jr, Bakris G, Greene T, et al. African American study of kidney disease and hypertension study group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431
22. Roggenenti P, Perna A, Loriga G, et al. REIN-2 study group: blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet 2005;365:939-946
23. Fujita T, Ando K, Nishimura H, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72:1543-1549
24. Morikawa T, Okumura M, Konishi Y, et al. Effects of benidipine on glomerular hemodyanamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002;25:571-576
25. Abe M, Okada K, Maruyama T, et al. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009;32:270-275
26. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992
27. Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008;73:1303-1309
28. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010;375:1173-1181
29. Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007;30:621-626
30. Yue W, Kimura S, Fujisawa Y, et al. Benidipine dilates both pre-and post-glomerular arteriole in the canine kidney. Hypertens Res 2001;24:429-436
31. Kawata T, Hashimoto S, Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997;30:431-436
32. Uneyama H, Uchida H, Konda T, et al. Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels. Eur J Pharmacol 1999;373:93-100
33. Murakami M, Mori T, Nakagawasai O, et al. Inhibitory effect of pranidipine on N-type voltage-dependent Ca channels in mice. Neurosci Lett 2004;367:118-122
34. Nap A, Mathy MJ, Balt JC, et al. The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists. Fund Clin Pharmacol 2004;18:309-319
35. Hayashi K, Wakino S, Sugano N, et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-353
36. Nagahama T, Hayashi K, Fujiwara K, et al. Characterization of the renal action of pranidipine in the rat. Arzneimittel Forschung 2000;50:248-253